GC 1 compound: Clinical Trials

2 trials of GC 1 compound, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 withdrawn. 2 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Withdrawn 2
Phase 21Withdrawn 1

Follow GC 1 compound: new trials by email Literature Review of GC 1 compound trials Research Report on GC 1 compound

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy
Sobetirome (NV1205) - X-Linked Adrenoleukodystrophy
Phase 1 / Phase 2WithdrawnNeuroVia, Inc.2018-08-012019-03-07
Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD)
Sobetirome - X-Linked Adrenoleukodystrophy, Adrenomyeloneuropathy
Phase 1WithdrawnThomas S. Scanlan2013-04-012014-02-14

Conditions studied

Adrenoleukodystrophy (2)  ·  Thyroid Diseases (1)

Sponsors

NeuroVia, Inc. (1)  ·  Thomas S. Scanlan (1)

Countries

Argentina (1)  ·  Australia (1)  ·  Chile (1)  ·  Colombia (1)  ·  France (1)  ·  Russia (1)  ·  Ukraine (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

David Koeller, MD (1)  ·  John Henderson, MD (1)